BALTIMORE, MD / ACCESSWIRE / January 5, 2021 / AsclepiX Therapeutics, Inc., a biopharmaceutical company using computational biology to identify…
Read More
What’s the biggest breakthrough in the ophthalmology space since Lucentis and Eylea? Novartis’ Beovu, launched last November for wet age-related…
Read More
Xconomy National — The body’s natural process for healing wounds has led AsclepiX Therapeutics to a novel approach to treating diseases of…
Read More
Proceeds to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials Series A financing led…
Read More
BALTIMORE, MD / ACCESSWIRE / January 6, 2020 / AsclepiX Therapeutics, Inc., a biopharmaceutical company that uses computational biology to identify…
Read More
To Provide Update on AXT107 Duration of Efficacy Maintained for Over Thirteen Months to Date in Animal Models AXT107 Inhibits…
Read More
GAITHERSBURG, Md. and NORWALK, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- NexImmune and the Multiple Myeloma Research Foundation (MMRF) have…
Read More
AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing novel peptide therapies, including AXT107 for retinal disease and novel peptides…
Read More
AXT107 exhibited a dual mechanism of action as a monotherapy, disrupting a key component of the Vascular Endothelial Growth Factor…
Read More
BALTIMORE--(BUSINESS WIRE)--AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing vital new therapies based on a novel peptide platform, today…
Read More
Johns Hopkins spinout AsclepiX Therapeutics raised $5 million in new funding that will assist in development of new treatment for eye diseases…
Read More